Revenue and losses both up at Cure Pharmaceutical
Oxnard-based Cure Pharmaceutical, a drug delivery platform and CBD products company, reported more losses but rising revenue in its second quarter earnings. Cure suffered a net loss of $9.6 million in the second quarter of 2022, up substantially from a net loss of $1.3 million in the same quarter a year ago. That equates to Read More →
Calavo shares dip after earnings report
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Ventura County’s Kolibri Energy strikes formula for growth in Oklahoma oil fields
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Portfolio Watch: Recessions and re-globalization
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Semtech shares hit two-year low after company lowers Q3 guidance
Camarillo-based Semtech produced record revenue and earnings in the second quarter of 2022, but its shares plummeted 27% the day after its earnings release after the company’s guidances for the third quarter were well below analysts’ expectations. Semtech, a semiconductor company specializing in Internet of Things applications, saw its net income increase in the second Read More →
Amgen reports pair of positive clinical trial results
Amgen announced positive results from clinical trials of two separate drugs in late August. On Aug. 30, the Thousand Oaks-based biotech giant said its Phase 3 trail evaluating daily oral doses of Lumakras, a treatment for non-small cell lung cancer, “met its primary endpoint of progression-free survival” and demonstrated statistically significant superiority over the current Read More →
Portfolio Watch: Don’t turn away from value stocks just yet, says UBS
• UBS writes that despite the recent rally in the S&P 500, it may not be time to shift away from a value orientation in picking equities. In a weekly update it tells investors that while “growth stocks have rallied sharply” from mid-June lows, “lingering uncertainty around inflation” and Fed moves “point toward further outperformance Read More →
